Article Figures & Data
Figures
- Fig. 1.
Radioimmunoimage of nude mice xenografted with tumor after injection with radiolabeled antibody.
Tables
Group Injected marked-drugs Injection approach Radioactivity (μCi) Volume injected (μl) 1 131I-IgG IT 50 38 2 131I + rituximab IT 50 11 3 131I-rituximab IP 50 11 4 131I-rituximab IT 50 11 IT, intratumor injection; IP, intraperitoneal injection; 131I + rituximab, mixing of 131I and rituximab.
Group Treatment protocol Injection approach Radioactivity MBq (μCi) Volume injected (μl) Types of tumor 1 0.05 MPB (nontreatment) IT 0 22 Raji 2 131I-NMIgG IT 5.55 (150) 22 Raji 3 131I-rituximab IP 5.55 (150) 22 Raji 4 131I-rituximab IT 2.78 (75) 22 Raji 5 131I-rituximab IT 5.55 (150) 22 Raji 6 131I-rituximab IT 5.55 (150) 22 Control Label Labeling yield (%) Radiochemical purity (%) Cell binding rate (%) Special radioactivity Volume [MBq (mCi)/ml] Weight [MBq (mCi)/mg] 131I-rituximab 72.4 95.2 28.5 170 (4.6) 244 (6.6) 131I-IgG 64.0 95.9 6.37 48 (1.3) 323 (8.7) - Table 4.
T/NT ratio of different radiolabeled antibodies in different sites of injection after various days.
Organ or tissue T/NT ratio 1 d 3 d 7 d 15 d IgG IT IP IgG IT IP IgG IT IP IT IP Blood 4.0 7.4 0.3 0.8 12.3 0.6 1.1 2.4 0.8 1.9 1.3 Muscle 39.3 125.3 3.1 9.8 153.4 4.8 14.4 24.4 8.7 17.8 12.9 Heart 19.4 30.1 1.6 4.6 62.6 2.4 5.9 10.3 3.3 8.7 6.1 Liver 10.2 23.3 1.2 2.7 78.1 2.6 4.2 9.5 3.2 9.6 5.8 Spleen 10.9 29.0 1.3 2.4 68.9 2.9 3.2 8.6 3.5 9.9 5.4 Lung 6.8 14.8 0.8 2.4 32.8 1.5 3.1 5.3 1.7 4.3 2.7 Kidney 11.9 25.5 1.0 3.1 55.8 2.2 5.3 8.5 3.1 7.8 4.8 Stomach 29.4 46.5 2.1 6.1 97.1 4.3 10.2 17.5 5.6 14.4 7.6 Small intestine 20.5 35.5 1.9 5.2 88.9 4.0 7.0 14.0 5.2 15.2 10.3 Large intestine 18.6 36.1 1.9 5.2 107.6 3.8 6.8 13.9 5.1 13.2 7.8 Bone 22.7 63.1 2.6 5.9 117.8 3.8 9.3 21.2 7.1 16.0 8.4 - Table 5.
The %ID/g of different radiolabeled antibodies in different sites of injection after various days.
Organ or tissue %ID/g value 1 d 3 d 7 d 15 d IgG IT IP IgG IT IP IgG IT IP IT IP Tumor 42.2 84.0 5.1 8.9 33.1 7.7 6.2 10.6 5.5 2.7 1.9 Blood 11.3 10.6 17.0 11.7 4.8 13.7 6.1 5.0 7.3 1.7 2.1 Muscle 1.6 0.8 1.7 0.9 0.5 1.7 0.5 0.5 0.6 1.0 0.2 Heart 2.4 2.6 3.5 1.9 1.2 3.3 1.1 1.1 1.4 0.4 0.5 Liver 4.5 4.5 4.3 3.1 1.1 3.1 1.5 1.1 1.4 0.3 0.5 Spleen 4.3 4.1 4.3 3.8 0.9 3.2 2.3 1.3 1.7 0.4 0.5 Lung 10.5 5.5 6.9 3.9 2.3 5.5 2.2 2.2 3.2 0.7 1.0 Kidney 3.8 3.3 4.5 2.8 1.2 3.6 1.3 1.3 2.0 0.4 0.6 Stomach 1.4 1.9 2.5 1.4 0.7 1.9 0.6 0.7 1.1 0.2 0.3 Small intestine 3.7 2.3 3.0 1.8 0.8 2.1 0.9 0.8 1.2 0.2 0.3 Large intestine 2.8 2.3 2.9 1.8 0.9 2.1 0.9 0.9 1.5 0.3 0.3 Bone 3.3 1.4 2.2 1.5 0.6 2.3 0.7 0.6 0.9 0.2 0.3 Group Cumulate absorption in tumor on different days after injection (Gy) 3 d 7 d 15 d 131I-IgG (IT) 5.15 5.65 13.99 131I-rituximab (IT) 10.83 13.90 21.65 131I-rituximab (IT) 0.86 2.32 3.09 131I-rituximab (IT) 0.07 0.10 0.46 Day Tumor volume ( 
)Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 1 1 1 1 1 1 1 3 1.93 ± 2.28 1.07 ± 0.30 1.61 ± 0.58 1.33 ± 0.30 1.31 ± 0.29 1.28 ± 0.24 5 2.62 ± 3.63 1.16 ± 0.16 2.10 ± 1.21 1.43 ± 0.37 1.28 ± 0.40 1.40 ± 0.38 7 2.42 ± 3.43 1.11 ± 0.40 1.86 ± 1.16 1.47 ± 0.54 1.05 ± 0.33 1.44 ± 0.29 10 2.29 ± 3.00 0.85 ± 0.40 1.60 ± 1.31 1.46 ± 0.68 1.25 ± 1.05 1.40 ± 0.46 12 2.29 ± 2.86 0.95 ± 0.74 1.87 ± 1.75 1.59 ± 0.85 1.26 ± 1.18 1.82 ± 0.80 14 2.33 ± 2.92 0.84 ± 0.80 1.74 ± 2.04 1.65 ± 0.90 1.06 ± 1.13 2.02 ± 0.97 17 1.98 ± 2.24 0.98 ± 1.28 1.65 ± 2.37 1.43 ± 1.02 0.98 ± 1.26 2.04 ± 1.25 19 1.80 ± 2.12 1.16 ± 1.78 1.59 ± 2.49 1.41 ± 1.13 0.91 ± 1.39 2.12 ± 1.35 21 1.54 ± 1.78 0.86 ± 1.30 1.42 ± 2.21 1.24 ± 1.13 0.58 ± 0.84 1.90 ± 1.37 24 1.41 ± 1.59 0.83 ± 1.41 1.39 ± 2.25 1.14 ± 1.07 0.52 ± 0.80 2.17 ± 1.74 26 1.18 ± 1.18 1.20 ± 2.12 1.33 ± 2.29 1.27 ± 1.23 0.53 ± 0.84 2.29 ± 1.83 28 1.04 ± 1.04 1.27 ± 2.26 1.32 ± 2.31 1.27 ± 1.25 0.49 ± 0.80 2.44 ± 2.05 31 1.01 ± 1.06 1.45 ± 2.74 1.25 ± 2.27 1.10 ± 1.10 0.34 ± 0.54 2.62 ± 2.19 33 1.02 ± 1.14 1.43 ± 2.68 1.14 ± 2.07 0.97 ± 0.96 0.39 ± 0.63 2.79 ± 2.36
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.